TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05150223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional strength training
Description: traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband). Participation in the traditional strength training group will complete these exercises with a load and without time limitations and speed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power training
Description: progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
Study: NCT04579653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation devices
Description: electrical stimulation through surface electrodes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation devices
Description: electrical stimulation through surface electrodes
Study: NCT04693611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual cognitive stimulation therapy (iCST)
Description: The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS)
Description: The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
Study: NCT05366582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal carbon dioxide (CO2). Failed intubation will be considered if not achieved within 2 minutes
Study: NCT06028100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacral erector spinae plane block
Description: espb from bilateral sacral level 2 with 20 ml %0,25 bupivacaine
Study: NCT03549403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered telephone education
Description: The intervention will be carried out in accordance with the guidelines and the contents of the patient-centered telephone education intervention in the same way with every patient. The education call duration is approximately 15 to 30 minutes.
Study: NCT06111391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osstell® device (Integration Diagnostics Ltd.).
Description: After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osstell® device (Integration Diagnostics Ltd.).
Description: After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).
Study: NCT05648071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
Study: NCT05837143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JV001
Description: JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory. Dose: 2×10\^11vg/kg，or 6×10\^11vg/kg.
Study: NCT05532787

Intervention type: OTHER
Intervention: Application of acute chest pain risk stratification scores (HEART and EDACS)
Description: Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
Study: NCT06108986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tabata training
Description: this include tabata training thrice a week for six weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric training
Description: this include plyometric training thrice a week for six weeks
Study: NCT05222490

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal Camera images acquisition - FeetSee
Description: Thermal images will be collected according to the instructions for use of the Feetsee device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Camera images acquisition - FeetSee
Description: Thermal images will be collected according to the instructions for use of the Feetsee device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Camera images acquisition - FeetSee
Description: Thermal images will be collected according to the instructions for use of the Feetsee device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal Camera images acquisition - Reference
Description: After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Camera images acquisition - Reference
Description: After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Camera images acquisition - Reference
Description: After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
Study: NCT05994495

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nuclear acid amplification tests
Description: The NAAT test will be performed with Bosch Vivalytic STI test. It is a qualitative Polymerase Chain Reaction-based assay for simultaneous detection of 10 common sexually transmitted pathogens: Herpes simplex virus 1 (HSV 1)- Herpes simplex virus 2 (HSV 2)- Chlamydia trachomatis (CT) - Haemophilus ducreyi (HD)- Mycoplasma genitalium (MG) - Mycoplasma hominis (MH) - Neisseria gonorrhoeae (NG) - Treponema pallidum (TP)- Ureaplasma urealyticum (UU) - Trichomonas vaginalis (TV)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Syndromic Approach
Description: Physical examination
Study: NCT04706117

Intervention type: DEVICE
Group type: OTHER
Intervention: Self-retaining bicanalicular intubation stent
Description: self-retaining bicanaliculs intubation setII(SRSII) which is the latest innovation in the field as these silicone stent segments traverse both canaliculi till the lacrimal sac. In which each end of this semicircular device has 2 stout angulated wings/flanges which pose no resistance while proceeding forward into the canaliculus, but once they get into open cavity (lacrimal sac), the flanges open up and give resistance to their removal against the common canalicular opening
Study: NCT06314620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin saline lock
Description: Participants with intercostal chest catheter who underwent normal saline flushing with heparin saline lock

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without heparin saline lock
Description: Participants with intercostal chest catheter who underwent normal saline flushing without heparin saline lock
Study: NCT05817071

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic massive rotator cuff repair
Description: Arthroscopic massive rotator cuff repair without biceps tendon augmentation either partial or complete repair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon
Description: Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon .
Study: NCT06386731

Intervention type: OTHER
Group type: OTHER
Intervention: Intermittent Phototherapy
Description: 2-hour phototherapy application in the intervention group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Phototherapy
Description: 2-hour phototherapy application in the intervention group
Study: NCT05993182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine 5mg
Description: Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine 10mg
Description: Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine 15mg
Description: Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
Study: NCT06295120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin 1.2 MIE 4 times daily
Description: The intervention is the duration of treatment with phenoxymethylpenicillin from 3 to 7 days. Dose and frequency of the treatment is the same in the different arms.
Study: NCT06305559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Description: Active treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baseline lipid modifying therapy
Study: NCT06375772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Deoxy-D-glucose
Description: Intranasal administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal administration
Study: NCT05574244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial surgery preserving the prostatic apex
Description: Partial Endoscopic resection of prostate to conserve apex

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional endoscopic prostatic surgery
Description: Endoscopic resection of prostate.
Study: NCT04883554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory therapeutic
Description: The sessions of the olfactory sensory therapy group take place according to the care framework at a frequency of one session of 45 minutes per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body therapy
Description: very specific stages at a weekly frequency and lasts 1 hour. Kinesic time or time to set the body in motion (20 min) Kinesthetic time: time of slow movements (20 min) Talk time (20 min)
Study: NCT05250557

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve
Description: Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve
Description: Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
Study: NCT06645704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP262
Description: Single dose of \[14C\]-EP262 administered orally.
Study: NCT03660722

Intervention type: OTHER
Group type: OTHER
Intervention: blood and urinary samples
Description: blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
Study: NCT05471856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1703880
Description: BI 1703880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab
Study: NCT05159960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
Study: NCT05305937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: All patients will be scanned twice during the same MRI session, before and 2 hours after taking glucosamine orally. In addition to the CEST scans with glucosamine, patients will undergo MRI scans with the standard contrast agent of gadolinium. This procedure will be done following the CEST scan
Study: NCT06782425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XKDCT225
Description: Autologous targeted claudin18.2 chimeric antigen receptor T cell injection
Study: NCT06781606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile transplantation
Description: The penile transplantation will take place at the Edouard Herriot hospital, part of the Hospices Civils de Lyon. It will be carried out on the same day or the day after the harvesting depending on the timing of the harvesting.
Study: NCT06780059

Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: Postoperative Radiotherapy with 3D-CRT and IMRT Techniques Following R0 Resection in BoPT and MPT Patients
Study: NCT04135443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3T Tune in! Turn on! Turn up!
Description: A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-19. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Materials Website
Description: The control group will receive access to a website containing general health promotion materials.
Study: NCT06324110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study: NCT06780059

Intervention type: PROCEDURE
Intervention: R0 resection
Description: Patients who received R0 resection (complete resection without tumor margin)

Intervention type: PROCEDURE
Intervention: R0 resection
Description: Patients who received R0 resection (complete resection without tumor margin)
Study: NCT06781528

Intervention type: OTHER
Intervention: Ultrasound evaluation
Description: All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.

Intervention type: OTHER
Intervention: Ultrasound evaluation
Description: All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.
Study: NCT06780202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medrol dosepak
Description: Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression.~This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg).
Study: NCT06324110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Receive lung cancer screening care coordination services
Study: NCT06345703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-136 matching placebo
Study: NCT06780202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYDROcodone Oral Tablet
Description: This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
Study: NCT06345703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-136 matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-136 matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-136 matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-136 matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-136 matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-136 tablet
Description: Investigational product NS-136
Study: NCT06780202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HYDROcodone Oral Tablet
Description: This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
Study: NCT06781294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Cytokine hemadsorption therapy
Description: Extracorporeal blood purification with oXiris set connected to cardiopulmonary bypass during all CPB time. Ultrafiltration was permitted.
Study: NCT06781996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal Resilience© digital companion
Description: Resilience© is a multi-component, multi-level interventional mobile application that will offer: (a) supportive educational care information (b) self-symptom management resources with availability of a remote health-care provider evaluation that addresses patient-specific needs in survivorship care and recommends personalized digital self-management resources at onboarding and if needed in case of low engagement in the mobile app.~Intervention duration : 3 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: standard of care provided by the oncologist and supportive care team at the patient local cancer center including referrals for local supportive care programs. Local supportive care programs may also include the use of already deployed remote patient monitoring and solutions, digital and in person education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard supportive care
Description: standard of care provided by the oncologist and supportive care team at the patient local cancer center including referrals for local supportive care programs. Local supportive care programs may also include the use of already deployed remote patient monitoring and solutions, digital and in person education.
Study: NCT06782217

Intervention type: BIOLOGICAL
Intervention: VENOX
Description: Treatment with allergy vaccine againts Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
Study: NCT05001165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Panel Management Clinics for HFrEF
Description: Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
Study: NCT05217966

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: Single Pre-Operative Radiation Therapy
Description: Ablative preoperative partial breast radiation therapy